Results 61 to 70 of about 100,010 (342)

Tau acetylation at K331 has limited impact on tau pathology in vivo

FEBS Letters, EarlyView.
We mapped tau post‐translational modifications in humanized MAPT knock‐in mice and in amyloid‐bearing double knock‐in mice. Acetylation within the repeat domain, particularly around K331, showed modest increases under amyloid pathology. To test functional relevance, we generated MAPTK331Q knock‐in mice.
Shoko Hashimoto, Yukio Matsuba, Mika Takahashi, Takaomi C. Saido   +3 more
wiley   +1 more source

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report

JTO Clinical and Research Reports, 2022
Antibody-drug conjugates targeting receptor tyrosine-protein kinase erbB-2 (ERBB2, HER2) have emerged as promising targeted options for HER2-mutant NSCLC.
Mariona Riudavets, MD, PhD, Arshid Azarine, MD, MSc, Sondes Smaali, MD, Young-Wouk Kim, MD, Vincent Thomas de Montpréville, MD, Alina Miruna Grecea, MD, Charles Naltet, MD, Annas Gazzah, MD, David Planchard, MD, PhD   +8 more
doaj   +1 more source

The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a. [PDF]

, 2013
p53 and its major E3 ligase Mdm2 are both ubiquitinated and targeted to the proteasome for degradation. Despite the importance of this in regulating the p53 pathway, little is known about the mechanisms of proteasomal recognition of ubiquitinated p53 and
A Arlt, A Haririnia, A Hishiya, A Peth, A Sparks, AK Hock, AM Ruschak, AS Fatimababy, B Cross, C Brignone, C Wojcik, CF Cheok, D Finley, D Pei, EG Mimnaugh, G Lozano, GL Bond, H Fu, H Fu, H Higashitsuji, H Hiyama, H Inuzuka, H Inuzuka, H Kawahara, HT Kim, I Dikic, J Boehringer, J Das, J Hamazaki, JD Oliner, JD Shaughnessy Jr., JM Stommel, JM Winget, K Husnjak, K Itahana, L Bedford, LF Stevenson, LJ Crawford, LK Linares, LR Dick, LT Vassilev, M Elangovan, M Elangovan, M Isasa, M K Saville, M Kaur, M Wade, M Wade, MD Kaeser, MF Kleijnen, MH Glickman, MJ Lee, MK Saville, MP Bousquet-Dubouch, N Allende-Vega, N Allende-Vega, N Allende-Vega, N Gallastegui, NP Dantuma, NP Dantuma, P Robertson, P Sdek, P Young, PG Santamaria, Q Xu, Q Zhu, R Kulikov, R Verma, S Carter, S Dayal, S Dayal, S Elsasser, S Glockzin, S Menendez, S Nickell, S Raasi, SJ Wei, T Kaneko, T Mayor, T Szlanka, TA Gomez, V Su, VD Nair, XM Sun, Y Jin, Y Kravtsova-Ivantsiv, Y Midorikawa, Y Saeki, Y Wan, YA Lam, YH Shen, YV Wang, Z Lipinszki, Z Lipinszki   +93 more
core   +3 more sources

Gut microbiome and aging—A dynamic interplay of microbes, metabolites, and the immune system

FEBS Letters, EarlyView.
Age‐dependent shifts in microbial communities engender shifts in microbial metabolite profiles. These in turn drive shifts in barrier surface permeability of the gut and brain and induce immune activation. When paired with preexisting age‐related chronic inflammation this increases the risk of neuroinflammation and neurodegenerative diseases.
Aaron Mehl, Eran Blacher
wiley   +1 more source

Antibody–Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic Considerations

Drugs in R&D
Melanoma is an aggressive, rapidly developing form of skin cancer that affects about 22 per 100,000 individuals. Treatment options for melanoma patients are limited and typically involve surgical excision of moles and chemotherapy.
Ina Lami, Andrew J. Wiemer
doaj   +1 more source

Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting [PDF]

, 2023
Katrin Schoenfeld, Julia Harwardt, Jan Habermann, Adrian Elter, Harald Kolmar   +4 more
openalex   +1 more source

The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells _in vitro_ and _in vivo_ [PDF]

, 2008
CD138 (Syndecan1) is highly expressed on multiple myeloma (MM) cells. In this study, we examined the anti-MM effect of murine/human chimeric CD138-specific monoclonal antibody (mAb) nBT062 conjugated with highly cytotoxic maytansinoid derivatives _in ...
Benjamin Dä, Christoph Uherek, Diana Cristea, Frank Osterroth, Giulia Perrone, Hiroshi Ikeda, Hiroshi Yasui, Kenneth C. Anderson, Loredana Santo, Mariateresa Fulciniti, Nikhil C. Munshi, Noopur S. Raje, Paul Richardson, Robert J. Lutz, Samantha Pozzi, Silkie Aigner, Sonia Vallet, Tanyel Kiziltepe, Teru Hideshima, Yu-Tzu Tai, Yutaka Okawa   +20 more
core   +1 more source

Hyperosmotic stress induces PARP1‐mediated HPF1‐dependent mono(ADP‐ribosyl)ation

FEBS Letters, EarlyView.
Sorbitol‐induced hyperosmotic stress rapidly induces reversible mono(ADP‐ribosyl)ation (MARylation) on PARP1 without the signs of genotoxic signaling. We show that PARP1 autoMARylation is HPF1 dependent and forms hydroxylamine‐resistant O‐glycosidic linkages.
Anna Georgina Kopasz, Mihály Mérey, Rebeka Vásárhelyi, Ramóna Pék, Victor Imburchia, László Henn, Adrián Kószó, Nicholas D. Lakin, Ivan Ahel, Sébastien Huet, Ágnes Czibula, Gyula Timinszky   +11 more
wiley   +1 more source

Antibody–drug conjugates in urothelial carcinoma: scientometric analysis and clinical trials analysis

Frontiers in Oncology
In 2020, bladder cancer, which commonly presents as urothelial carcinoma, became the 10th most common malignancy. For patients with metastatic urothelial carcinoma, the standard first-line treatment remains platinum-based chemotherapy, with immunotherapy
Meng Zhang, Yuanye Zuo, Siyi Chen, Yaonan Li, Yang Xing, Lei Yang, Hong Wang, Rui Guo   +7 more
doaj   +1 more source

Introduction of Carbonyl Groups into Antibodies

Molecules, 2023
Antibodies and their derivatives (scFv, Fabs, etc.) represent a unique class of biomolecules that combine selectivity with the ability to target drug delivery.
Evgeny L. Gulyak, Vera A. Alferova, Vladimir A. Korshun, Ksenia A. Sapozhnikova   +3 more
doaj   +1 more source